BACKGROUND _ AIMS: A hypothesis suggesting that profound acid inhibition therapy facilitates and hastens the development of @entity356 in @entity1 infected with @entity1534 was investigated in this randomized study comparing @entity4546 therapy with @entity1104 ( @entity1104 ) for chronic @entity354 ( @entity354 ). METHODS: @entity1 with @entity2910 and/or chronic @entity354 were enrolled; 155 @entity1 were randomized to @entity1104 and 155 to long-term @entity4546 therapy. Baseline data were obtained and repeated after 3 years in 131 @entity1104 @entity1 and in 139 @entity4546 -treated @entity1 . Histopathologic status of the oxyntic mucosa was assessed according to the Sydney system. RESULTS: Forty @entity4546 -treated @entity1 were infected with @entity1534 compared with 53 in the @entity1104 group. Basal @entity8243 levels were significantly higher in @entity1534 -infected @entity1 , particularly in the @entity4546 group. No further increases in serum @entity8243 levels were observed during 3 years. Despite 3 years of therapy, only slight changes were found in the prevalence of @entity32 in the corpus mucosa of @entity1534 -infected subjects. A slow progression of @entity356 was observed in these @entity1 irrespective of therapy with no obvious difference between treatment regimens. @entity1944 (all of type I) was only exceptionally observed with no difference between the treatment arms. CONCLUSIONS: Acid-suppressive therapy in the form of @entity4546 maintained for 3 years facilitates neither the development of @entity356 of the corpus mucosa nor the occurrence of intestinal metaplasia in @entity1534 -infected @entity354 @entity1 .

Lack of effect of acid suppression therapy on XXXX . Nordic Gerd Study Group.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1944 :: ('MESH:D007410', 'Disease') :: ['Intestinal metaplasia'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity8243 :: ('2520', 'Gene') :: ['gastrin'] @entity1534 :: ('210', 'Species') :: ['H. pylori', 'Helicobacter pylori'] @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux disease', 'GERD'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['antireflux surgery', 'ARS'] @entity4546 :: ('MESH:D009853', 'Chemical') :: ['omeprazole'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric glandular atrophy']
@entity356 :: (MESH:D013274,Disease) :: ['gastric atrophy']
